SOURCE: CDEX, Inc.

December 03, 2007 09:45 ET

CDEX, Inc. Announces Amendments to Bylaws to Strengthen Corporate Structure and Restructuring of Board of Director Committees

TUCSON, AZ--(Marketwire - December 3, 2007) - CDEX, Inc. (OTCBB: CEXI) announces that effective November 27, 2007, it has taken steps to strengthen its Corporate structure by amending its Bylaws and realigning its Board of Director Committees. "With the growing number of ValiMed™ hospital clients and commercialization of our Methamphetamine Scanner, we are receiving increasing national and international visibility and inquiries regarding our company," said Malcolm Philips, CEO and Chairman of the Board of CDEX, Inc. "In the face of this increasing exposure, the Board instituted Bylaw changes to strengthen the corporate structure. In addition, taking advantage of the expanding expertise on our Board, we have restructured Committee assignments and adopted new Committee Charters for our Audit, Compensation and Corporate Governance Committees. These steps will result in a more structured Board oversight of CDEX company actions, providing greater protection for our shareholders." The amendments to the Bylaw are detailed in the required SEC 8K filed on December 2, 2007.

The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication's spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand "validated" or "not validated" result, requiring no user interpretation.

The Methamphetamine Scanner uses the same basic technology employed in ValiMed to identify trace quantities of methamphetamine on all surfaces while in a continuous scan mode. The Scanner, weighing less than 11/2 pounds, is battery operated, handheld, non intrusive and requires no operator interpretation of results. The Scanner is undergoing final testing and is expected to be available for delivery in the first quarter of 2008.

About CDEX, Inc.

CDEX, Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed™ is a CDEX solution for the healthcare market. Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm Philips (mphilips@cdex-inc.com) or Stuart Poteet (spoteet@cdex-inc.com) at 520.745.5172 X 210 or 202.

Any statements made in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in the federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the company to raise capital to finance the development of its products, the effectiveness, profitability and marketability of those products, the ability of the company to protect its proprietary information, the establishment of an efficient corporate operating structure as the company grows and, other risks detailed from time-to-time in filings with the securities and exchange commission. There is no obligation to publicly update any forward-looking statements.

Contact Information